Get the Stockscreener App
14.22
8.14%
1.07
After Hours:
14.24
0.02
+0.14%
Corvus Pharmaceuticals Inc stock is traded at $14.22, with a volume of 1.30M.
It is up +8.14% in the last 24 hours and down -21.87% over the past month.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
See More
Previous Close:
$13.15
Open:
$13.39
24h Volume:
1.30M
Relative Volume:
0.39
Market Cap:
$1.19B
Revenue:
-
Net Income/Loss:
$-15.28M
P/E Ratio:
-28.10
EPS:
-0.5061
Net Cash Flow:
$-32.97M
1W Performance:
+0.99%
1M Performance:
-21.87%
6M Performance:
+115.13%
1Y Performance:
+261.83%
1-Day Range:
$13.31
$14.54
1-Week Range:
$12.95
$14.54
52-Week Range:
$2.54
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
14.22 | 1.10B | 0 | -15.28M | -32.97M | -0.5061 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 8.4% HigherTime to Buy? - MarketBeat
Income Plays: Can Corvus Pharmaceuticals Inc beat the S P 5002026 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Is Corvus Pharmaceuticals Inc forming a breakout pattern2026 Growth vs Value & Accurate Buy Signal Notifications - baoquankhu1.vn
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - MSN
Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Is Corvus Pharmaceuticals’ Expanded US$200 Million ATM Facility Reframing Its Funding Story for CRVS? - Sahm
Growth Recap: Will Corvus Pharmaceuticals Inc outperform tech stocksEarnings Overview Report & Daily Stock Trend Watchlist - baoquankhu1.vn
A Look At Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Swings - Sahm
FY2030 Earnings Forecast for CRVS Issued By HC Wainwright - MarketBeat
Corvus outlines cash runway into Q2 2028 and targets mid-2027 Phase II readout for soquelitinib in atopic dermatitis - MSN
Corvus Trials Progress And Cash Raise Reframe Soquelitinib Risk Reward Profile - Sahm
Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline - TipRanks
CRVS Stock Receives Analyst Rating and Price Target Boost from O - GuruFocus
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price Gains - Yahoo Finance
Corvus Pharmaceuticals (NASDAQ:CRVS) Given Outperform Rating at Oppenheimer - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 6.5% After Earnings Miss - MarketBeat
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Corvus Pharmaceuticals, Inc. has signed a revised equity distribution agreement. - Bitget
Corvus Pharmaceuticals Expands ATM Equity Program to $200 Million With Jefferies - TradingView
Corvus Pharmaceuticals (NASDAQ: CRVS) launches $200M at-the-market stock program - Stock Titan
Corvus Pharmaceuticals (NASDAQ: CRVS) doubles Jefferies ATM capacity to $200M - Stock Titan
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Corvus Pharmaceuticals (CRVS) files S-3 shelf to offer stock, debt, warrants - Stock Titan
Oppenheimer raises Corvus Pharmaceuticals stock price target to $33 By Investing.com - Investing.com Canada
Corvus: Q4 Earnings Snapshot - theheraldreview.com
Corvus Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Corvus Pharmaceuticals rises on atopic dermatitis trial data By Investing.com - Investing.com Australia
Decoding Corvus Pharmaceuticals Inc (CRVS): A Strategic SWOT Ins - GuruFocus
Corvus: Fourth Quarter Earnings Overview - Bitget
Earnings call transcript: Corvus Pharmaceuticals Q4 2025 Misses EPS Forecast - Investing.com
CRVS: Strong clinical and financial momentum with soquelitinib, supporting pipeline expansion and durability - TradingView
Corvus Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Corvus Pharmaceuticals (NASDAQ:CRVS) Issues Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Corvus Pharmaceuticals 2025 Financial Report: Quarterly & Annual Results | CRVSNews and Statistics - IndexBox
Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings - TipRanks
Corvus Pharmaceuticals rises on atopic dermatitis trial data - Investing.com
CORVUS PHARMACEUTICALS ($CRVS) Releases Q4 2025 Earnings - Quiver Quantitative
Corvus Pharmaceuticals (NASDAQ: CRVS) highlights soquelitinib Phase 3 and Phase 2 trials - Stock Titan
Corvus Pharmaceuticals 10‑K: $0 Revenue, $(0.19) EPS (basic) — net loss $(15.28M) - TradingView
Corvus Pharmaceuticals (NASDAQ: CRVS) posts 2025 results and $189.4M financing boost - Stock Titan
Corvus eczema drug posts positive early data and $189M cash boost - Stock Titan
Corvus Pharmaceuticals earnings on deck after positive trial data By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals earnings on deck after positive trial data - Investing.com
Earnings Scheduled For March 12, 2026 - Benzinga
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Earnings: Is Corvus Pharmaceuticals Inc being accumulated by smart money2026 Technical Overview & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Corvus Pharmaceuticals (CRVS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Corvus Pharmaceuticals (CRVS) soars 212% on impressive eczema therapy study - MSN
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):